Post hoc analysis of DapaTAVI (1222 TAVI patients): dapagliflozin was linked to lower 1-year death or worsening heart failure in frail patients (HR 0.53) but not prefrail (HR 1.01) or robust (HR 1.26); interaction P=0.021. Frailty itself predicted worse outcomes.
Secondary analysisn = 1,222
Gonzalez-Manzanares et al. Dapagliflozin After Transcatheter Aortic Valve Implantation According to Frailty in DapaTAVI Trial